Orientation for New Clinical Research Personnel
VirtualThis six-part orientation is strongly recommended for all clinical research personnel who are new to research or new to UNC-Chapel Hill.
This six-part orientation is strongly recommended for all clinical research personnel who are new to research or new to UNC-Chapel Hill.
Robert Agans, PhD researches new methods to produce cost-effective population-based estimates for gender and sexual minorities. In this seminar, Agans will highlight recent findings using a new technique developed at UNC, including some health disparity data between transgender and cisgender people.
Join Andrew Roberts, PharmD, PhD for a presentation of findings from his KL2-funded work examining high-risk opioid use patterns and outcomes in older adult cancer survivors.
Join this month's COVID-19 journal club to discuss the use of real world data to evaluate the effectiveness of the BNT162b2 mRNA vaccine.
Join NC TraCS and the UNC Center for AIDS Research for the Spring 2021 edition of the Implementation Science Speaker Series, featuring Carolyn Audet, PhD, Assistant Professor of Health Policy and Epidemiology and Assistant Director of Community Based Implementation Research at Vanderbilt University. In this seminar, Audet will discuss engagement of traditional healers in the delivery of evidence-based HIV testing and treatment support in rural South Africa.
Join NC TraCS and the UNC Center for AIDS Research for the Spring 2021 edition of the Implementation Science Speaker Series, featuring Carolyn Audet, PhD, Assistant Professor of Health Policy and Epidemiology and Assistant Director of Community Based Implementation Research at Vanderbilt University. In this seminar, Audet will discuss engagement of traditional healers in the delivery of evidence-based HIV testing and treatment support in rural South Africa.
This six-part orientation is strongly recommended for all clinical research personnel who are new to research or new to UNC-Chapel Hill.
Join CTSA visiting scholar Hanny Al-Samkari, MD, as he discusses the use of bevacizumab, a humanized monoclonal antibody that targets VEGF, to treat hereditary hemorrhagic telangiectasia (HHT) — a rare disorder that causes anemia and often requires transfusions to treat.
Join Hanny Al-Samkari, MD for a presentation describing the revolutionary potential of anti-angiogenic therapy in hereditary hemorrhagic telangiectasia (HHT) and the evidence to date for systemic bevacizumab as a treatment for bleeding and anemia in HHT.
The REDCap Forms Training Session (beginner) will teach users to build forms using the online designer or data dictionary (lecture/demo).
This six-part orientation is strongly recommended for all clinical research personnel who are new to research or new to UNC-Chapel Hill.
This interactive beginner course will teach users to build forms using the online designer or data dictionary.